Cancer immunotherapy

Nov 22, 2024

NK cell therapies have demonstrated significant clinical efficacy, with studies reporting response rates ranging from 40% to 80% in certain hematologic malignancies. As of recent data, several NK cell therapy candidates are in clinical trials, with notable successes including improved overall survival rates and red...

May 17, 2024

iTeos shares jump by 40%. GSK and iTeos collaboration for Belrestotug looks like a worthy wait. Hopes to ward off the negative sentiments around the volatile TIGIT space? In the ever-evolving landscape of cancer immunotherapy, the pursuit of effective treatment strategies continues to drive innovation and invest...

Dec 29, 2023

Hematopoietic progenitor kinase (HPK1) belongs to the family of Ste20 serine/threonine kinases known as mitogen-activated protein kinase kinase kinase kinase (MAP4K). It is primarily expressed in hematopoietic cells and functions as a negative regulator of T-cell receptor (TCR) and B-cell signaling, serving as an i...

Mar 17, 2023

Oncology has become a growing area of interest for pharmaceutical companies over the years. With a significant increase in R&D and healthcare spending worldwide, companies ranging from large pharmaceutical conglomerates to smaller biotech organizations are frantically attempting to capitalize on lucrative marke...

Dec 06, 2021

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a relatively new immunological checkpoint that has been studied as a potential immunotherapeutic target. TIGIT is a transmembrane glycoprotein receptor containing an Ig-like V-type domain in its cytoplasmic domain and an ITIM in its extracellular domain. It'...